Advertisement

Topics

FDA Advances Genentech's Zelboraf to Treat Rare Blood Disease

10:11 EDT 7 Aug 2017 | PharmPro

FDA grants Priority Review and Breakthrough Therapy designation for Zelboraf (vemurafenib) in Erdheim-Chester disease with BRAF V600 mutation. Currently, there are no FDA-approved treatments for the rare blood disease.
Contributed Author: 
Genentech
Topics: 

Original Article: FDA Advances Genentech's Zelboraf to Treat Rare Blood Disease

NEXT ARTICLE

More From BioPortfolio on "FDA Advances Genentech's Zelboraf to Treat Rare Blood Disease"

Quick Search
Advertisement
 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...